Drug Therapy: Oral Phosphate Binders in Patients with Kidney Failure.

被引：258

作者：

Tonelli, Marcello ^{[1
,2
]}

Pannu, Neesh ^{[1
,3
]}

Manns, Braden ^{[4
,5
]}

机构：

[1] Univ Alberta, Dept Med, Edmonton, AB, Canada

[2] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada

[3] Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada

[4] Univ Calgary, Dept Med, Calgary, AB, Canada

[5] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 362卷 / 14期

基金：

加拿大健康研究院;

关键词：

CORONARY-ARTERY CALCIFICATION; CHRONIC-HEMODIALYSIS PATIENTS; CHRONIC-RENAL-FAILURE; LANTHANUM CARBONATE; CALCIUM-CARBONATE; SEVELAMER-HYDROCHLORIDE; DIALYSIS PATIENTS; MAGNESIUM CARBONATE; ALUMINUM-HYDROXIDE; SERUM PHOSPHORUS;

D O I：

10.1056/NEJMra0912522

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperphosphatemia, which is nearly universal in kidney failure, is accompanied by low serum levels of vitamin D and hypocalcemia. Without treatment, severe secondary hyperparathyroidism occurs, which may result in painful fractures, brown tumors, and generalized osteopenia. This article reviews the rationale for treatment with oral phosphate binders, discusses evidence supporting the use of available agents, and suggests an approach for clinical practice. Copyright © 2010 Massachusetts Medical Society. All rights reserved.

引用

页码：1312 / 1324

页数：13

共 109 条

[11]

Braun J, 2004, CLIN NEPHROL, V62, P104

[12]

BRINGHURST FR, 2004, HARRISONS PRINCIPLES, V2, P2238

[13] Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis [J].

Bro, S ;

Rasmussen, RA ;

Handberg, J ;

Olgaard, K ;

Feldt-Rasmussen, B .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (02) :257-262

[14] Sevelamer hydrochloride (Renagel®), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers [J].

Burke, SK ;

Amin, NS ;

Incerti, C ;

Plone, MA ;

Lee, JW .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (02) :199-205

[15] Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients [J].

Caglar, Kayser ;

Yilmaz, Mahmut Ilker ;

Saglam, Mutlu ;

Cakir, Erdinc ;

Acikel, Cengizhan ;

Eyileten, Tayfun ;

Yenicesu, Mujdat ;

Oguz, Yusuf ;

Vural, Abdulgaffar ;

Carrero, Juan Jesus ;

Axelsson, Jonas ;

Lindholm, Bengt ;

Stenvinkel, Peter .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :61-68

[16]

*CAN AG DRUGS TECH, 2008, CEDAC FIN REC REC RE

[17] Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients [J].

Caravaca, F ;

Fernandez, MA ;

Ruiz-Calero, R ;

Cubero, J ;

Aparicio, A ;

Jimenez, F ;

Garcia, MC .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (10) :2605-2611

[18] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].

Chertow, GM ;

Burke, SK ;

Raggi, P .

KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252

[19]

Chiang SS, 2005, CLIN NEPHROL, V63, P461

[20] Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life - A randomized controlled trial [J].

Culleton, Bruce F. ;

Walsh, Michael ;

Klarenbach, Scott W. ;

Mortis, Garth ;

Scott-Douglas, Narine ;

Quinn, Robert R. ;

Tonelli, Marcello ;

Donnelly, Sarah ;

Friedrich, Matthias G. ;

Kumar, Andreas ;

Mahallati, Houman ;

Hemmelgarn, Brenda R. ;

Manns, Braden J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (11) :1291-1299

← 1 2 3 4 5 6 7 8 9 10 →